Japan Grants Astellas' Prograf Approval For Additional Indication Myasthenia Gravis
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Astellas' immunosuppressant for organ transplant Prograf (tacrolimus) was granted an additional indication approval by Japan's Ministry for Health, Labor and Welfare for myasthenia gravis, an autoimmune disorder characterized by muscle weakness and fatigue, the company reported Oct. 16